Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glyburide vs Glucovance in Gestational Diabetes
NCT02726490Phase 1Terminated
- Sponsor
- Texas Tech University Health Sciences Center
- Start
- Jul 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glibenclamide + metformin in gestational diabetes mellitus (GDM) (2 arms), sponsored by Texas Tech University Health Sciences Center. Primary endpoint: Efficacy of glyburide compared to glucovance. Started Jul 2016; status: terminated.
02
Drugs
glibenclamide + metformin
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on NCT02726490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726490.